Cargando…
Oral antiseptics against coronavirus: in-vitro and clinical evidence
Angiotensin converting enzyme 2 (ACE2) is the cellular receptor for SARS-CoV-2, so ACE2-expressing cells can act as target cells and are susceptible to infection. ACE2 receptors are highly expressed in the oral cavity, so this may be a potential high-risk route for SARS-CoV-2 infection. Furthermore,...
Autores principales: | Mateos-Moreno, M.V., Mira, A., Ausina-Márquez, V., Ferrer, M.D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Healthcare Infection Society. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046704/ https://www.ncbi.nlm.nih.gov/pubmed/33865974 http://dx.doi.org/10.1016/j.jhin.2021.04.004 |
Ejemplares similares
-
Re: Oral antiseptics against coronavirus: in-vitro and clinical evidence
por: Amoah, G.B., et al.
Publicado: (2021) -
Effect of oral antiseptics in reducing SARS-CoV-2 infectivity: evidence from a randomized double-blind clinical trial
por: Sánchez Barrueco, Álvaro, et al.
Publicado: (2022) -
Clinical evaluation of antiseptic mouth rinses to reduce salivary load of SARS-CoV-2
por: Ferrer, Maria D., et al.
Publicado: (2021) -
Characterization of clinically used oral antiseptics as quadruplex-binding ligands
por: Calabrese, David R, et al.
Publicado: (2018) -
Development of antiseptic adaptation and cross-adapatation in selected oral pathogens in vitro
por: Verspecht, Tim, et al.
Publicado: (2019)